Maymetsi (Metformin Hydrochloride, Sitagliptin)

Metformin lowers hepatic glucose production and increases peripheral insulin sensitivity, while sitagliptin inhibits the enzyme dipeptidyl‑peptidase‑4 (DPP‑4). This inhibition prolongs the activity of incretin hormones, leading to glucose‑dependent insulin secretion and reduced glucagon release. The combined actions address both insulin resistance and impaired insulin secretion in type 2 diabetes.

The dosage of Maymetsi is individualized by the prescribing healthcare professional based on the patient’s current glycaemic status, renal function, and concomitant medications. The prescriber determines the appropriate strength and dosing schedule, which may be taken once daily with meals. Patients should follow the exact instructions provided on the prescription label.

Safety of Maymetsi in pregnancy and lactation has not been fully established. Metformin is sometimes used when benefits outweigh risks, whereas sitagliptin is generally avoided. Healthcare providers should evaluate the risk‑benefit profile for each patient, and women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatment options with their clinician.

To place an order, submit an enquiry on the Maymetsi product page at gnhindia.com, specifying the required quantity and providing institutional or trade credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, then confirms pricing, availability, shipping terms and any necessary import documentation before finalising the supply.

Compared with metformin alone, the addition of sitagliptin provides an incretin‑based mechanism that can further lower HbA1c without increasing weight. Unlike sulfonylureas, the combination has a lower intrinsic risk of hypoglycaemia. It offers a convenient single‑tablet regimen versus separate prescriptions, but cost and individual patient response should be considered when selecting therapy.

Maymetsi tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister or bottle to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured. No refrigeration is required.

Maymetsi is taken orally, usually once daily with a meal to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not split, crushed or chewed unless specifically instructed by a healthcare professional. Consistent timing each day helps maintain stable drug levels and optimises glycaemic control.

The most serious adverse events include lactic acidosis, which is rare but can be fatal, and acute pancreatitis linked to the sitagliptin component. Severe hypersensitivity reactions such as anaphylaxis may also occur. Patients should seek immediate medical attention if they experience unexplained muscle pain, rapid breathing, abdominal pain, persistent vomiting, or signs of an allergic reaction.

Maymetsi is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any excipients, and those with a history of lactic acidosis. It should also be avoided in individuals with acute or chronic metabolic acidosis, including diabetic ketoacidosis. Clinicians must assess each patient’s medical history before prescribing.